Clinical trials: High-Risk Cancer, open to volunteers
Prostate Cancer
Adaptive Versus Non-adaptive Radiotherapy and 2 Bladder Filling Instructions for Patients With Intermediate or High Risk Localized Prostate Cancer (ARP)
The study is being done to compare the side effects between two different radiation techniques, standard non-adaptive radiation therapy vs.
- Trial name
- NCT06678126
- Testing
- Prostate and Pelvic Nodes Radiotherapy
- Where
- Canada
- Volunteers
- 104 people
- Sponsor
- Scott Tyldesley
Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
This phase II trial tests how well remdesivir works for treatment of respiratory syncytial virus (RSV) infection of the upper respiratory tract in patients receiving cellular or bispecific antibody therapy.
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease, Respiratory Syncytial Virus Infection
- Trial name
- NCT06817889
- Testing
- Remdesivir, Survey Administration, Biospecimen Collection
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma
To evaluate the efficacy and safety of mitoxantrone Hydrochloride Hydrochloride Liposome combination regimen in the treatment of high-risk/extramedullary multiple myeloma
- Trial name
- NCT06246162
- Testing
- Lipo-MIT combination regimen
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital of Nantong University
Rectal Cancer
Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria
Why is this study conducted? The purpose of this study is to improve the treatment efficacy, particularly the pathological complete response rate, in patients with high-risk/extremely high-risk locally advanced rectal cancer…
- Trial name
- STARS-RC10 (NCT07505472)
- Testing
- Experimental Group, Control group
- Where
- China
- Volunteers
- 212 people
- Sponsor
- The First Hospital of Jilin University
High-Grade Glioma, Glioblastoma
APT-weighted and Diffusion MRI for Characterizing Tumor Infiltration in High-Grade Gliomas
High-grade gliomas are the most common primary malignant brain tumors and are characterized by infiltration of the surrounding brain tissue beyond the visible tumor margins.
- Conditions
- High-Grade Glioma, Glioblastoma, Brain Tumor Adult
- Trial name
- APT-HGG (NCT07532031)
- Testing
- Standard-of-care MRI data, including APT and diffusion imaging, will be analyzed to generate quantitative maps of tumor infiltration within the peri-tumoral region.
- Volunteers
- 20 people
- Sponsor
- IRCCS Ospedale San Raffaele
Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL)
Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy
The goal of this Phase 2, open-label, multicenter clinical trial is to assess the efficacy and safety of accelerated ramp-up and fixed-dose subcutaneous epcoritamab combined with lenalidomide in adults with relapsed or refractory…
- Conditions
- Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL), Refractory T-cell/Histiocyte-rich Large B-cell Lymphoma, Refractory Transformed Follicular Lymphoma
- Trial name
- BiFAST (NCT07814001)
- Testing
- Epcoritamab, Lenalidomide
- Where
- 15 sites in France
- Volunteers
- 55 people
- Sponsor
- The Lymphoma Academic Research Organisation
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma
This phase I trial tests the effect of allogeneic Orca-Q stem cell transplant in treating patients with high-risk multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous…
- Trial name
- NCT07759102
- Testing
- Allogeneic Defined Hematopoietic Stem Cells/Immune Cells, Busulfan, Filgrastim
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Ovarian Cancer, High Grade Ovarian Serous Adenocarcinoma
High Definition Profiling of Ovarian Cancer Ascites
This project entails the collection of a prospective cohort of ascites (AS) samples from High Grade Serous Ovarian Cancer (HGSOC) patients.
- Conditions
- Ovarian Cancer, High Grade Ovarian Serous Adenocarcinoma, Ascites
- Trial name
- NCT06553742
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- European Institute of Oncology
Hepatocellular Carcinoma (HCC)
WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy
urgical treatment represents a critical approach for HCC patients to achieve long-term survival, primarily including hepatectomy and liver transplantation.
- Trial name
- NCT07077369
- Testing
- WGc-0201 injection, Tislelizumab
- Volunteers
- 10 people
- Sponsor
- West China Hospital
Cancer, Genetic Predisposition
EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer
5 to 10% of cancers are due to the presence of a constitutional genetic alteration. It can be inherited from parents (family form) or by accident, in the first moments of life after fertilization (sporadic form).
- Trial name
- EX²TRICAN (NCT04141462)
- Testing
- blood sample
- Where
- 6 sites in France
- Volunteers
- 613 people
- Sponsor
- Centre Georges Francois Leclerc
Breast Cancer
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
The study is being conducted to evaluate the efficacy and safety of HRS-8080 in patients with intermediate or high risk early breast cancer.
- Trial name
- NCT07349069
- Testing
- HRS-8080 Tablets, Letrozole tablets, Tamoxifen Citrate Tablets
- Where
- 2 sites in China
- Volunteers
- 5,500 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are…
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT06451497
- Testing
- ZM008
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Zumutor Biologics Inc.
Breast Cancer
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA)…
- Trial name
- NCT06401421
- Testing
- ctDNA MRD test
- Where
- 61 sites in United States, Canada
- Volunteers
- 1,800 people
- Sponsor
- Exact Sciences Corporation
Colorectal Cancer
MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer
The aim of this clinical trial is to test whether minimal residual disease (MRD) status detected by circulating tumor DNA (ctDNA) could be used to guide precision therapy of post-surgery in colon cancer.
- Trial name
- MIRROR (NCT06204484)
- Testing
- CAPEOX adjuvant therapy, deferred CAPEOX adjuvant therapy, mFOLFOXIRI intensive adjuvant therapy
- Where
- China
- Volunteers
- 349 people
- Sponsor
- Sun Yat-sen University
Appendiceal Cancer, Colorectal Adenocarcinoma
A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis
This study will evaluate the role of mass-based response testing (MRT) to select and deliver personalized hyperthermic intraperitoneal chemotherapy (HIPEC) regimens to patients with peritoneal metastasis (PM) from high-grade…
- Conditions
- Appendiceal Cancer, Colorectal Adenocarcinoma, Peritoneal Metastases
- Trial name
- NCT07291180
- Testing
- Mass-based response testing (MRT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
High-risk Neuroblastoma, Neuroblastoma
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.
- Conditions
- High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma
- Trial name
- NCT06528496
- Testing
- DANYELZA, Sargramostim, Cytoxan
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Neoplasms, Fluorescence
Fluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon Cancer
To explore the short-term and long-term outcomes of fluorescence laparoscopic navigation D2 lymph node dissection for colorectal cancer surgery by comparing it with D3 lymph node dissection.
- Conditions
- Colorectal Neoplasms, Fluorescence, Lymph Node Excision
- Trial name
- FLORA-01 (NCT05730595)
- Testing
- lymph node dissection
- Where
- 19 sites in China
- Volunteers
- 550 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lymphoma, Large B-Cell, Diffuse
A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL
Comparison of MODIFIED progression-free survival (Modified-PFS) in high-dose rituximab (500mg/m²) plus CHOP versus standard-dose rituximab plus CHOP in previously untreated (TN) stage III-IV male DLBCL patients
- Trial name
- NCT06573645
- Testing
- Rituximab
- Volunteers
- 428 people
- Sponsor
- Xia Yi
Nasopharyngeal Carcinoma, De-escalation Therapy
Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
This prospective trial aims to enroll patients with high-risk stage III-IVA (AJCC 8th, except T3N0) locoregionally-advanced nasopharyngeal carcinoma (LANPC).
- Trial name
- NCT06092957
- Testing
- Cisplatin-based induction chemotherapy, Full course of PD-1/PD-L1 blockades, Reduced-dose IMRT
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer
Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment
With people living longer after being treated for prostate cancer, quality of life has become a concern when considering the treatment plan.
- Trial name
- VORTEX (NCT07293585)
- Testing
- Neurovascular sparing stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Jonsson Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.